Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thermostable Flolan lifestyle impact study in pulmonary arterial hypertension
2011-002943-92Phase 4Terminated
- Sponsor
- GSK
- Start
- Aug 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epoprostenol in pulmonary arterial hypertension (PAH), sponsored by GSK. Primary endpoint: Quality of life assessment using SF-36 questionnaire. Started Aug 2011; status: terminated.
02
Drugs
epoprostenol
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2011-002943-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002943-92.